HAG
LSTA icon

HighPoint Advisor Group’s Lisata Therapeutics LSTA Stock Holding History

HighPoint Advisor Group’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-95
Closed -$10K – 289
2016
Q1 		$10K Sell
95
-3
-3% -$295 0.01% 223
2015
Q4 		$9K Hold
98
– – 0.01% 203
2015
Q3 		$22K Buy
+98
New +$24.6K 0.02% 138

Other funds holding LSTA

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

HighPoint Advisor Group's LSTA Position: Q2 2016 in Review

HighPoint Advisor Group sold out of Lisata Therapeutics (LSTA) in Q2 2016, closing a stake of 95 shares — an estimated $10K sold.

HighPoint Advisor Group first reported a position in LSTA in Q3 2015 and held it in 3 quarters. The position peaked at $22K in Q3 2015. 43 funds tracked by Wall St. Rank hold LSTA as of Q2 2016.

  • HighPoint Advisor Group reported no remaining Lisata Therapeutics position as of Q2 2016 after selling out during the quarter.
  • HighPoint Advisor Group sold 95 Lisata Therapeutics shares in Q2 2016, an estimated $10K.
  • HighPoint Advisor Group first reported a position in Lisata Therapeutics in Q3 2015 and held it in 3 quarters.
  • HighPoint Advisor Group's Lisata Therapeutics position peaked at $22K in Q3 2015.
  • 43 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q2 2016.

Based on HighPoint Advisor Group's 13F filing for Q2 2016, filed 10 Aug 2016.